According to a statement from Bahrain’s Ministry of Health, citizens and residents over the age of 18 can register to receive the free vaccine.
The cited data, as announced earlier this month by the United Arab Emirates, are from an interim analysis of post-clinical trials for inactivated vaccine by the Beijing Institute of Biological Product, Sinofarmin China National Biotech Group (CNPG).
In July, the United Arab Emirates began phase 3 clinical trials for the vaccine and extended the trial to Bahrain, Jordan and Egypt.
No CNPG or synopsis was available for comment.
The Bahraini report said that the Kingdom had participated in the 3rd phase of testing of the approved vaccine and had previously approved it for emergency use by leading experts.
Earlier this month, Bahrain granted emergency use approval for the Pfizer / Bioentech vaccine.
In the fellow Gulf Arab state of Kuwait, the Ministry of Health on Sunday approved emergency use of the Pfizer / Bioentech vaccine, state news agency Guna reported.
The Peruvian government said in a statement on Saturday that this came after Peru suspended tests for the synoform vaccine due to a “severe adverse event” that occurred to one of the volunteers for the study.
The Ministry of Health said the incident was “under investigation to determine if it is related to the vaccine or has a different interpretation”.
Synopharm, which is conducting tests in Peru with about 12,000 volunteers, was about to complete the first phase of testing.
“The decision to temporarily suspend clinical trials is a precautionary measure considered in the regulations for established protocols to protect the health of clinical trials and research subjects,” the health ministry said in a statement.
German Malaga, a lead researcher at the local Guidano Heredia University involved in the study, said a volunteer had weak legs and other symptoms.